Deborah A Hall Selected Research

Tinnitus

1/2022	Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial.
1/2021	Modifiable lifestyle-related risk factors for tinnitus in the general population: An overview of smoking, alcohol, body mass index and caffeine intake.
1/2021	The spatial percept of tinnitus is associated with hearing asymmetry: Subgroup comparisons.
1/2021	Emerging Topics in the Behavioral Neuroscience of Tinnitus.
10/2020	Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study.
7/2020	Evaluation of a Cognitive Behavioral Model of Tinnitus Distress: A Cross-Sectional Study Using Structural Equation Modeling.
1/2020	Protocol for a multi-centre randomised controlled stand-alone feasibility trial to assess potential effectiveness and cost-effectiveness of digital hearing aids in patients with tinnitus and hearing loss (the HUSH trial).
9/2019	Noninvasive Bimodal Neuromodulation for the Treatment of Tinnitus: Protocol for a Second Large-Scale Double-Blind Randomized Clinical Trial to Optimize Stimulation Parameters.
1/2019	Association Between Residual Inhibition and Neural Activity in Patients with Tinnitus: Protocol for a Controlled Within- and Between-Subject Comparison Study.
1/2019	Impact of Temporomandibular Joint Complaints on Tinnitus-Related Distress.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deborah A Hall Research Topics

Disease

31	Tinnitus 01/2022 - 07/2011
14	Fragile X Tremor Ataxia Syndrome 12/2022 - 11/2005
10	Parkinson Disease (Parkinson's Disease) 05/2022 - 11/2012
4	Parkinsonian Disorders (Parkinsonism) 01/2022 - 10/2006
4	Tremor (Tremors) 10/2020 - 10/2006
3	Movement Disorders (Movement Disorder) 02/2022 - 10/2006
3	Hearing Loss (Hearing Impairment) 01/2020 - 07/2015
2	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2022 - 12/2019
2	Deafness (Deaf Mutism) 03/2021 - 03/2020
2	Neoplasms (Cancer) 01/2021 - 01/2018
2	Hypokinesia (Bradykinesia) 10/2020 - 04/2014
2	Cognitive Dysfunction 01/2020 - 10/2006
2	Hypertension (High Blood Pressure) 01/2019 - 01/2018
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2018 - 05/2013
2	Intellectual Disability (Idiocy) 01/2016 - 08/2011
1	Acute-Phase Reaction 02/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Multiple System Atrophy 01/2022
1	Synucleinopathies 01/2022
1	Kidney Diseases (Kidney Disease) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 11/2021
1	Dyskinesias (Dyskinesia) 11/2021
1	Vertigo (Positional Vertigo) 01/2021
1	Benign Paroxysmal Positional Vertigo 01/2021
1	Dizziness (Lightheadedness) 01/2021
1	Sensorineural Hearing Loss 03/2020
1	Hyperlipidemias (Hyperlipidemia) 01/2019
1	Diabetes Mellitus 01/2019
1	Noise-Induced Hearing Loss (Acoustic Trauma) 01/2019
1	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2018
1	Ear Diseases (Disease, Ear) 03/2018
1	Hidden Hearing Loss 03/2018
1	Infarction (Infarctions) 01/2018

Drug/Important Bio-Agent (IBA)

6	Messenger RNA (mRNA)IBA 01/2018 - 11/2005
5	Pharmaceutical PreparationsIBA 01/2022 - 09/2017
3	Proteins (Proteins, Gene)FDA Link 02/2022 - 04/2004
2	ProteomeIBA 02/2022 - 02/2022
2	Therapeutic UsesIBA 01/2022 - 09/2019
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 01/2021
2	5' Untranslated Regions (5' UTR)IBA 01/2022 - 01/2016
2	Peptides (Polypeptides)IBA 01/2022 - 01/2018
2	Silver Sulfadiazine (SSD)FDA LinkGeneric 03/2021 - 03/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2018
2	Memantine (Namenda)FDA Link 04/2020 - 10/2010
2	propylene diquat (PDQ(+))IBA 01/2020 - 11/2012
2	Indicators and Reagents (Reagents)IBA 01/2019 - 10/2017
2	Biomarkers (Surrogate Marker)IBA 03/2018 - 01/2016
2	Fragile X Mental Retardation ProteinIBA 01/2018 - 05/2013
1	CytosineIBA 12/2022
1	GuanineIBA 12/2022
1	AlbuminsIBA 02/2022
1	Cell Adhesion MoleculesIBA 02/2022
1	Biological ProductsIBA 02/2022
1	Cathepsin BIBA 02/2022
1	Liver X ReceptorsIBA 02/2022
1	Retinoid X Receptors (Retinoid X Receptor)IBA 02/2022
1	ApolipoproteinsIBA 02/2022
1	CholesterolIBA 02/2022
1	Apolipoprotein C-II (ApoC2)IBA 02/2022
1	Amyloid (Amyloid Fibrils)IBA 02/2022
1	trimethyloxamine (trimethylamine N-oxide)IBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Succinic Acid (Succinate)IBA 01/2022
1	Butyric Acid (Butanoic Acid)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Volatile Fatty AcidsIBA 01/2022
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2022
1	Levodopa (L Dopa)FDA LinkGeneric 11/2021
1	Dopamine Agonists (Dopamine Agonist)IBA 11/2021
1	Caffeine (No Doz)FDA LinkGeneric 01/2021
1	Hormones (Hormone)IBA 01/2021
1	IncretinsIBA 01/2021
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021
1	Neuroprotective AgentsIBA 01/2021
1	hydroxide ionIBA 10/2020
1	Cytidine Diphosphate Choline (Citicoline)IBA 01/2020
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2020
1	Chemokine CCL5IBA 12/2019
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2019
1	AUT00063IBA 01/2019
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	Betahistine (Serc)IBA 12/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018
1	polyglycineIBA 01/2018
1	polyalanineIBA 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	oxidized low density lipoproteinIBA 01/2018
1	PlatinumIBA 01/2018

Therapy/Procedure

18	Therapeutics 11/2021 - 10/2006
8	Hearing Aids (Hearing Aid) 01/2021 - 07/2011
4	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
2	CARE protocol 05/2022 - 01/2017
2	Aftercare (After-Treatment) 10/2020 - 04/2004
2	Relaxation Therapy (Relaxation Technique) 12/2018 - 12/2018
1	Deep Brain Stimulation 01/2019
1	Dental Care 01/2019
1	Contraindications 03/2018